News

September 18, 2019

IMV, Wistar Institute Partner to Develop T-cell Immunotherapy Against Cancers with BRAF Mutations

News

IMV announced that it has joined with the Wistar Institute to develop an immunotherapy targeting cancer cells with mutations in the BRAF gene. Such mutations are linked to some types ... Read more

September 16, 2019

Collaborators Aim to Identify OC Patients Likely to Benefit from New Combo Therapy

News

The University of New Mexico (UNM) Comprehensive Cancer Center and the New Mexico Alliance for Cancer Care have entered a collaboration with Personalis to use its cancer immunogenomics platform ... Read more

September 13, 2019

TCR2 Therapeutics, National Cancer Institute Team Up to Develop TC-210 Immunotherapy

News

TCR2 Therapeutics has partnered with Raffit Hassan, MD, at the National Cancer Institute to test TC-210, a mesothelin-specific immunotherapy, in an ongoing Phase 1/2 clinical trial for people with ... Read more

September 11, 2019

Activities Underway to Mark Ovarian Cancer Awareness Month

News

Efforts including financial assistance, fundraising and education are underway to mark Ovarian Cancer Awareness Month. The annual September observance includes specialty lender Fifth Season Financial, which seeks to ease ... Read more

September 9, 2019

Assay Shows Potential in Predicting Ovarian Cancer Response to Chemotherapy

News

A new assay that grows patients’ cancer tissue in the lab and tests for treatment sensitivity may be able to spot ovarian cancer patients likely to respond best to ... Read more

September 6, 2019September 6, 2019

Ampligen Combo Safe, Effective in Treating Recurrent Ovarian Cancer, Phase 1 Study Shows

News

A combination of Hemispherx Biopharma‘s investigational treatment Ampligen (rintatolimod) with chemo-immunotherapy is safe and effective in treating women with recurrent ovarian cancer, according to the final report of a ... Read more

September 4, 2019September 4, 2019

‘Don’t Eat Me’ Signal CD24 May Be Promising Therapeutic Target for Ovarian and Breast Cancers, Study Says

News

Researchers have discovered a “don’t eat me” signal that is deployed by ovarian and breast cancer cells to evade a person’s immune system. Similar to other anti-cancer therapies in ... Read more

August 30, 2019September 4, 2019

Research into Tumor Suppressor P53 in Ovarian Cancer Receives $1.8M NIH Grant

News

A research team at the David Geffen School of Medicine at UCLA received a $1.8 million, five-year grant from the National Institutes of Health (NIH) to develop new therapeutic ... Read more

August 28, 2019

Expert Discusses Celsion’s Ovarian Cancer Immunotherapy GEN-1; Phase 1/2 Trial Still Enrolling

News

The ovarian cancer immunotherapy candidate GEN-1, which is being tested in a Phase 1/2 clinical trial in newly diagnosed patients with advanced disease, was the focus of a recent call ... Read more

August 26, 2019

Rubraca Conditionally Rejected for Use on NHS England for Recurrent Ovarian Cancer

News

Rubraca (rucaparib), a therapy for relapsed or progressive ovarian, fallopian, or primary peritoneal cancer, was provisionally rejected for use on England’s National Health Service (NHS). In justifying its decision, ... Read more

Pin It on Pinterest